(Albany, US) On November 04, 2026, DelveInsight’s “Hyperkalemia Market Insights, Epidemiology and Market Forecast – 2036” report provides comprehensive insights into the Hyperkalemia market and treatment landscape across the 7MM. It covers marketed drug profiles and the status of the pipeline. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type, and examines the market drivers and barriers shaping the space.
Discover the latest drugs and treatment options in the Hyperkalemia Market @ https://www.delveinsight.com/report-store/hyperkalemia-market
Key Takeaways from the Hyperkalemia Report
In August 2026, Lupin received US FDA approval for its generic sodium zirconium cyclosilicate for oral suspension, a therapeutic equivalent to LOKELMA that expands patient access in the US.
In October 2025, AstraZeneca completed a USD 445 million expansion of its Coppell, Texas facility, doubling production capacity for LOKELMA. LOKELMA sales were USD 542 million in 2024, up 32% year over year.
In March 2025, Zeria Pharmaceutical launched patiromer (VELTASSA) in Japan, a once-daily oral powder for suspension in-licensed from CSL Vifor. In September 2024, Japan’s MHLW approved it, bringing total approvals to 41 countries.
LOKELMA received broader NHS support after being among the first medicines evaluated under NICE’s higher cost-effectiveness threshold.
Mild hyperkalemia accounted for the largest share of severity-specific cases in the US in 2025, followed by moderate and severe.
The hyperkalemia pipeline is sparse, with no notable emerging therapies in advanced clinical development, so growth is expected to come from broader use of existing therapies, better monitoring, and rising diagnosis.
Leading Hyperkalemia companies include AstraZeneca, CSL Vifor, Zeria Pharmaceutical, and others.
Key therapies include sodium zirconium cyclosilicate (LOKELMA), patiromer (VELTASSA), and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hyperkalemia Treatment Drugs
Hyperkalemia Overview
Hyperkalemia is an electrolyte disorder of elevated blood potassium that can impair neuromuscular and cardiac function. It most often results from reduced renal potassium excretion, excessive intake, or shifts of potassium out of cells, and is frequently linked to chronic kidney disease, heart failure, diabetes, and medicines such as RAAS inhibitors and potassium-sparing diuretics. Severe hyperkalemia can cause life-threatening arrhythmias. Diagnosis relies on serum potassium, electrolyte panels, renal function tests, and ECG. Management includes dietary modification, medication adjustment, potassium binders such as LOKELMA and VELTASSA, diuretics, insulin with glucose, β2-agonists, and dialysis in severe cases.
Key features include:
Elevated serum potassium
Risk of cardiac arrhythmia
Strong link to CKD, heart failure, and diabetes
High recurrence in at-risk patients
Need for regular potassium monitoring
Hyperkalemia Marketed Drugs Profile
Sodium Zirconium Cyclosilicate (LOKELMA): AstraZeneca LOKELMA is an insoluble, non-absorbed oral potassium binder, given as a powder for suspension. It captures potassium in the gastrointestinal tract in exchange for sodium and hydrogen ions, increasing fecal potassium excretion. It was approved by the FDA in 2018 and a generic version was approved in the US in August 2026. Currently, the drug is marketed.
Patiromer (VELTASSA): CSL Vifor/Zeria Pharmaceutical VELTASSA is a non-absorbed oral cation exchange polymer suspension that exchanges calcium for potassium in the colon. It is indicated for chronic hyperkalemia and supports continued use of RAAS inhibitors at optimal doses. It was first approved in the US in 2015, with Zeria holding rights in Japan. Currently, the drug is marketed.
Explore the marketed therapies and pipeline status in the Hyperkalemia Market @ Hyperkalemia Treatment Drugs
Hyperkalemia Market Drivers
Rising prevalence: Growing CKD, heart failure, and diabetes burdens, especially among older adults, are expanding the patient pool.
Use of RAAS inhibitors: Guideline-recommended therapies raise potassium levels and sustain demand for long-term potassium control.
Established binders: LOKELMA and VELTASSA enable continued use of cardiovascular and renal therapies.
Better monitoring and diagnosis: Routine potassium testing in high-risk patients increases detection and treatment.
Expanding access: The NICE decision on LOKELMA, VELTASSA’s Japan launch, and a US generic widen availability.
Manufacturing scale-up: AstraZeneca’s capacity expansion supports supply and growth.
Learn about new drugs, market developments, and key players with DelveInsight’s expert analysis @ Hyperkalemia Market Drivers and Barriers
Hyperkalemia Market Barriers
No emerging pipeline: Few late-stage candidates mean limited innovation and little near-term change.
Generic erosion: The August 2026 US generic of LOKELMA may pressure branded pricing and share.
Established therapy duopoly: Two binders dominate, so new entrants face a high bar.
Tolerability and convenience: Gastrointestinal effects and long-term suitability remain concerns.
Under-monitoring: Delays in testing and recurrent hyperkalemia identification in high-risk patients limit treatment.
Reimbursement pressure: Payers may favor lower-cost options and impose step requirements.
Single-site supply for LOKELMA: The sole global production site concentrates supply risk.
Scope of the Hyperkalemia Report
Coverage: 7MM (US, EU4, UK, Japan)
Companies: As listed above
Therapies: Sodium zirconium cyclosilicate (LOKELMA), patiromer (VELTASSA), and others
Assessment by Product Type: Mono, Combination, Mono/Combination
Assessment by Clinical Stage: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight’s in-depth Hyperkalemia report today! @ Hyperkalemia Companies
Table of Contents
Introduction
Executive Summary
Hyperkalemia: Overview
Pipeline Therapeutics
Therapeutic Assessment
DelveInsight’s Analytical Perspective
Late Stage Products (Phase III): None currently
Mid Stage Products (Phase II): None currently
Early Stage Products (Phase I): None currently
Preclinical and Discovery Stage Products
Inactive Products
Key Companies
Key Products
Unmet Needs
Market Drivers and Barriers
Future Perspectives and Conclusion
Analyst Views
Appendix
About Us
About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Mehul MalhotraEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 NV 89107City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting
